NYSEARCA:AZTR - NYSE Arca - US05479L2034 - Common Stock - Currency: USD
NYSEARCA:AZTR (2/26/2025, 12:32:49 PM)
0.3725
+0.02 (+6.43%)
The current stock price of AZTR is 0.3725 USD. In the past month the price increased by 39.94%. In the past year, price decreased by -95%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.03 | 358.27B | ||
AMGN | AMGEN INC | 15.51 | 165.12B | ||
GILD | GILEAD SCIENCES INC | 24.01 | 137.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1663.67 | 123.95B | ||
REGN | REGENERON PHARMACEUTICALS | 15.48 | 77.24B | ||
ARGX | ARGENX SE - ADR | N/A | 38.21B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.07B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.73B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.13B | ||
NTRA | NATERA INC | N/A | 21.35B | ||
BIIB | BIOGEN INC | 8.51 | 20.42B | ||
GMAB | GENMAB A/S -SP ADR | 24.42 | 14.43B |
Azitra Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Branford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2023-06-16. Azitra, Inc. is an early-stage clinical biopharmaceutical company. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. The Company’s product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
AZITRA INC
21 Business Park Drive, Suite 6
Branford CONNECTICUT US
Employees: 10
Company Website: https://azitrainc.com/
Phone: 12034890183
The current stock price of AZTR is 0.3725 USD. The price increased by 6.43% in the last trading session.
The exchange symbol of AZITRA INC is AZTR and it is listed on the NYSE Arca exchange.
AZTR stock is listed on the NYSE Arca exchange.
7 analysts have analysed AZTR and the average price target is 3.57 USD. This implies a price increase of 858.39% is expected in the next year compared to the current price of 0.3725. Check the AZITRA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AZITRA INC (AZTR) has a market capitalization of 6.82M USD. This makes AZTR a Nano Cap stock.
AZITRA INC (AZTR) currently has 10 employees.
AZITRA INC (AZTR) has a support level at 0.34 and a resistance level at 0.39. Check the full technical report for a detailed analysis of AZTR support and resistance levels.
The Revenue of AZITRA INC (AZTR) is expected to decline by -68.88% in the next year. Check the estimates tab for more information on the AZTR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AZTR does not pay a dividend.
AZITRA INC (AZTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.48).
The outstanding short interest for AZITRA INC (AZTR) is 4.64% of its float. Check the ownership tab for more information on the AZTR short interest.
ChartMill assigns a technical rating of 1 / 10 to AZTR. When comparing the yearly performance of all stocks, AZTR is a bad performer in the overall market: 97.61% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to AZTR. AZTR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months AZTR reported a non-GAAP Earnings per Share(EPS) of -7.48. The EPS decreased by -127.06% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -92.34% | ||
ROE | -112.04% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to AZTR. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 95.94% and a revenue growth -68.88% for AZTR